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EVALUATION OF LENTIVIRAL VECTORS FOR HUMAN
PANCREATIC CANCER GENE THERAPY
G Saraga, E Costello, P Ghaneh 
United Kingdom, University of Liverpool, Department of Surgery, Liverpool
Aims: 1. To examine the suitability of lentiviral vectors (LV), based on the
equine infectious anaemia virus (EIAV) and human immunodeﬁ  ciency virus 
type-1 (HIV-1) as a gene delivery system for pancreatic cancer gene therapy 
and compare their efﬁ  ciency.2.To deliver and determine the long-term stability 
of CapG, a cytoskeleton regulating protein, identiﬁ  ed in our laboratory to be
differentially expressed in PDAC cells compared to normal cells. Methods:
Vectors (Oxford Biomedica UK) were produced by co-transfection of 293T
cells with 1 ) a packaging construct, 2) a transfer construct encoding t he
enhanced green ﬂ  uorescence protein (EGFP) and 3) a plasmid expressing
the vesicular stomatitis virus  glycoprotein  (VSV-G) envelope protein.
Vectors were concentrated by ultracentrifugation and titered on 293T cells.
Particle/infectivity ratio was estimated by viral RNA assays. The efﬁ  ciency of 
transduction was evaluated by FACS analysis for detection of EGFP. The CapG
gene was cloned into the EIAV system harbouring the Neomycin resistance
gene for selection of transduced cells and overexpression was determined 
by immunoblotting. Growth curves were constructed to investigate possible
interference of the vector (cells transduced with a control vector) with normal
cell growth (non-transduced cells). Results: Five pancreatic cancer cell lines
(Panc-1, MiaPACA, Suit-2, BxPc3 and CFPAC1) have been examined and 
were all successfully transduced by either HIV or/and EIAV vectors. Low 
MOIs of 2, 3 and 10 for both vectors resulted in transduction efﬁ  ciencies
ranging from 3% to 47% of EGFP+ cells. Long-term overexpression of CapG
was monitored for six months. No growth differences were observed between 
transduced and non-transduced cells. Conclusions:  Both EIAV and HIV-
based LV vectors can efﬁ  ciently transduce pancreatic cancer cells. Current 
work involves evaluation of the vectors for infection of primary pancreatic
cancer cells and also investigation of the effects of CapG overexpression. LV
vectors are able of permanent integration into the host’s DNA and there has
been no toxicity associated with their use. We believe that LV vectors will
make useful tools in pancreatic cancer research but also offer potential for 
pancreatic cancer gene therapy approaches.
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IN VITRO STUDIES ON NOVEL OESTROGENIC POLYAMINE 
DRUG CONJUGATES
H Mackay 1, RM Phillips 2, JE Brown 3, S Carrington 1
1 University of Bradford, Bradford, UK, 2 Tom Connors Cancer 
Research Centre, Bradford, UK, 3 Kingston University,
Kingston-upon-Thames, UK
Polyamines are low molecular weight compounds, which have  been
established to play key roles in cellular growth and proliferation.
Polyamines can enter cells via the speciﬁ  c polyamine transport system
(PTS), whose expression is found to be upregulated in rapidly growing
tumours making them a popular target for antitumour drug design
(Delcros et al, 2002, J. Med. Chem.  45: 5098). Oestrogen receptor
(ER) positive (>10fmol receptor/mg cytosolic protein) (Whittliff, 1984,
Cancer 53: 630) breast tumours are known to display a dependency on
oestrogens to maintain cell growth. It is, thereby, our aim to develop
targeted antitumour agents containing polyamines, which are selective
towards cells expressing the oestrogen receptor.
A trifunctional drug conjugate was synthesised which incorporated
an  oestrogen ligand and an intercalating acridine moiety linked via
the polyamine spermine (SPM). This compound was evaluated in
chemosensitivity tests using the cultured human breast cancer cell lines
MCF-7  (ER+ve) and Hs578t (ER-ve). Percentage cell survival was
determined after 96h exposure, using drugs in the range 0.001-100µM,
via the colourimetric MTT assay (Jabber et al 1989, Br. J. Cancer 60:
523). In addition doxorubicin (DOX), currently used to treat breast
cancer, was also tested for a comparison of activity. 
These data indicate that the trifunctional conjugate is less potent than
DOX  (36.7µM a gainst 0.25µM  in MCF-7). However, the conjugate
does show µM activity and shows selectivity towards the ER positive
cell line (36.7µM in MCF-7 against 40µM in Hs578t), hence, making it
a suitable lead compound for current ongoing investigations.
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TARGETING MULTIPLE REPAIR PATHWAYS SUBSTANTIALLY
ENHANCES THE SENSITIVITY OF HUMAN OVARIAN TUMOUR 
CELLS TO TEMOZOLOMIDE 
VA. Barvaux 1, P Lorigan 2, M. Ranson 2, A. Gillum 3, R. Brown 4,
R.S. McElhinney 5, TBH. McMurry 5, G.P. Margison 1
1 Paterson Institute for Cancer Research, Manchester, United 
Kingdom, 2 Christie Hospital, Manchester, United Kingdom, 3 Genta 
Incorporated, Berkeley Heights, United States, 4 Beatson Laboratories,
Glasgow, United Kingdom, 5 Trinity College, Dublin, Ireland
Temozolomide is an alkylating agent that mediates its cytotoxic effectsvia
O6-methylguanine (O6-meG) adducts in DNA and their recognition and 
processing by the postreplication mismatch repair system (MMR). O6-
meG adducts can be repaired by the DNA repair protein O6-alkylguanine-
DNA-alkyltransferase  (MGMT), which therefore constitutes a major 
resistance mechanism to the drug. Resistance to Temozolomide can 
also be mediated by loss of MMR, which is frequently mediated by 
methylation of the hMLH1 gene promoter. Methylation of hMLH1 can 
be reversed by treatment of cells with 5-aza-2’-deoxycytidine, while the
MGMT pseudosubstrate O6-(4-bromothenyl)guanine (PaTrin-2; PatrinTM;
lomeguatribBAN, KuDOS) can deplete MGMT activity. Using a drug
resistant cell line which expresses MGMT and has methylated hMLH1, we
show that while either of these treatments can individually sensitize cells
to Temozolomide, the combined treatment leads to substantially greater 
sensitization. The increased sensitization is not observed in matched 
MMR proﬁ  cient cells. Furthermore, we show that attenuation of the
anti-apoptotic protein Bcl-2 by the antisense oligonucleotide Oblimersen 
sodium (GenasenseTM, Aventis/Genta) leads to the sensitization of the
MMR proﬁ  cient cells. This effect is also enhanced by the combined 
treatment of Oblimersen and PaTrin-2.
This work is supported by the European Union Marie Curie Individual
Fellowship  (proposal  no 2000-02021), the Bourse post-doctorale de
recherche scientiﬁ  que  (Mai 2000) of the Université Catholique de
Louvain, Belgium, and Cancer Research UK
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IS 3, 4, 4’ ,5-TETRAMETHOXYSTILBENE (DMU212) A BETTER 
CANCER CHEMOPREVENTIVE AGENT THAN TRANS-3,4’, S-3,4’, S
5-TRIHYDROXYSTILBENE (RESVERATROL)?
S Sale 1, RG Tunstall 1, GA Potter 2, WP Steward 1, AJ Gescher 1
1 United Kingdom, Leicester University, Leicester, 2 United Kingdom,
DeMontfort University, Leicester
Resveratrol is a naturally occurring polyphenol with cancer
chemopreventive properties  in preclinical models of carcinogenesis,
including those of colorectal cancer.  Recently a novel analogue of
resveratrol, DMU212 has been found to exhibit preferential growth-
inhibitory and pro-apoptotic properties in transformed cells, when
compared w ith t heir untransformed counterparts (Lu  et  al.,  2001
Carcinogenesis,22: 321), this activity was superior to that of resveratrol.
In order to aid the rational development of resveratrol and DMU212
as colorectal cancer preventive agents, ApcMin/+ m ice r eceived t hese
stilbenes, at three different doses (0.05, 0.2 and 0.5% admixed in the
diet), from weanling age to 18 weeks. At 18 weeks adenoma numbers
were scored. Resveratrol at all doses reduced adenoma number to 96.7
± 31.1, 73.2 ± 9.6, and 69.7 ± 12.7 per cent of control, respectively, the
two higher doses being signiﬁ  cantly different from control (p<0.05).
DMU212 at the same doses reduced adenoma number to 85.0 ± 16.0,
76.1 ± 8.2 and 88.1 ± 21.9 per cent of the control, respectively. The
difference was signiﬁ  cant only in the case of the 0.2% dose (p<0.05).
COX-2, which is thought to contribute to cancer progression, was
measured by Western blotting in HCA-7 colon cancer cells after
incubation with stilbenes  for 24, 48 and 96 hr. Resveratrol s howed
signiﬁ  cant inhibitory effects on COX-2 expression at 48hr and 96 hrs
at 10µM (p<0.05), whilst DMU212 had a minimal effect. Prostaglandin
E2 (PGE2), a product of COX enzyme activity and an indirect indicator
of COX-2 activity, was also investigated. Resveratrol and DMU212
showed similar effects on PGE2 levels, with 10 and 50µM being the
most potent, causing up to 96% reduction. These ﬁ  ndings provide a
clue as to the mode of action of these compounds. These results provide
a strong rationale to further investigate resveratrol and DMU212 as
possible colorectal cancer chemopreventive agents.
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ANTI-METASTATIC EFFECTS OF THE BISPHOSPHONATE
ESTER APOMINE IN BREAST CANCER CELL LINES IN VITRO
LM Pickering, LC Lowe, SJ Ganguli, JL Mansi, KW Colston
St. George’s Hospital Medical School, London, United Kingdom
Apomine is a novel 1,1-bisphosphonate ester that inhibits cholesterol
synthesis through mevalonate pathway inhibition and mimics the effects
of farnesol in vitro. Unlike conventional bisphosphonates, it does not
localise exclusively to bone and has a plasma half-life of 156 hours.
There is little data addressing the anti-neoplastic effects of apomine but
growth inhibitory and apoptotic effects have been observed in a number 
of cancer cell types, mediated through activation of the farnesoid X
receptor (FXR), and we have described apoptosis induction in breast
cancer cells in vitro. Breast cancer metastasises to bone in one third of 
cases and adhesion of cancer cells to bone matrix is one critical step
in this process. This study therefore investigated the consequences of 
apomine treatment for breast cancer cell adhesion.
Breast cancer cell lines (n=2) were exposed to apomine for 24 - 72
hours. Equal numbers of v iable cells were seeded onto mineralised 
dentine and unmineralised protein matrices for 1-24 hours. Adherent
cells were washed, ﬁ  xed, stained and the dye eluted or cells counted.
Cell growth and viability were assessed by Sulforhodamine B and MTS
dye reduction assay.
Breast cancer cells adhered to all matrices under control conditions.
Exposure to apomine for 24 hours at concentrations of 1 and 10
microM was associated with 79 and 83% reduction in adhesion, 26 and 
52% inhibition of proliferation but insigniﬁ  cant reduction in viability.
Prolonged treatment with 10 microM apomine resulted in more
pronounced reduction in proliferation and viability by up to 73 and 54%
respectively after 3 days of treatment.
This study conﬁ  rms  that apomine  has growth  inhibitory properties
in breast cancer cells and provides the ﬁ  rst demonstration that it also
inhibits their adhesion. Future studies will determine whether this effect
is mediated by FXR activation or mevalonate pathway inhibition. These
ﬁ  ndings indicate that apomine has clinical anti-metastatic potential.
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DEVELOPMENT OF A REAL-TIME RT-PCR ASSAY FOR THE 
QUANTIFICATION OF DRUG-METABOLISING ENZYMES AND
TARGET OF CAPECITABINE
JS Macpherson 1, S Guichard 2, DI Jodrell 2
1 Cancer Research UK, Edinburgh, United Kingdom, 2 University of 
Edinburgh, Edinburgh, United Kingdom
Capecitabine is a new ﬂ   uoropyrimidine, prodrug of 5-ﬂ  uorouracil 
(5FU) approved for the chemotherapeutic treatment of breast and colon 
cancers. Capecitabine is metabolised in both liver and tumour tissues 
by carboxylesterases (hCES), cytidine deaminase (CDD) and thymidine 
phosphorylase (TP) to form 5FU, which is inactivated by dihydropyrimidine 
dehydrogenase (DPD) reducing its capacity for interaction with its target, 
thymidylate synthase (TS). These enzymes have different distributions in 
liver and tumour tissue and may impact on the activation/inactivation of the 
drug.  We have developed a real-time PCR assay to determine the expression 
of the 2 isoforms of carboxylesterase (hCES1 and hCES2), CDD, TP, DPD 
and TS in a panel of 6 colon cancer cell lines. RT-PCR was performed 
on a Rotorgene 3000 (Corbett Research).  Calibration curves were made 
from HCT-8 RNA (0.05-50 ng) and results expressed as equivalent ng of 
HCT-8 RNA. The precision of the method was evaluated within-runs and 
in-between runs on 2 different batches of RNA. Three out of 6 cell lines lack 
CES1 expression and SW620 had a very low level (0.05±0.02 eq ng HCT-8 
RNA). CES2 expression varied from 0.38±0.08 in HCT-116 to 2.6±0.1 in 
SW620.  CDD expression ranged from 0.3±0.03 in SW620 cells to 4.9±0.7 
in COLO205.  HT29 and HCT-116 had very high levels of TP (18±4 and 
15±6, respectively). Variability between replicates within the same run was 
low and variability of 18S between subsequent runs within the same RNA 
batch ranged from 0.01% for SW620 to 20% for HT-29. Variability between 
batches was greater varying from 7-22% for CES1, to 13-68% for CDD. 
The use of 18S to normalize the results decreased only the variability of 
CDD expression. The real-time PCR method developed is reproducible and 
the variability between batches could be linked to the conﬂ  uency of the 
cells used for RNA preparation. This method could also be used in patients 
treated with the drug.
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PROTEIN PRENYL TRANSFERASE INHIBITION IN PROSTATE 
CANCER USING AZD3409
R. Khafagy 1, T.C. Stephens 2, C. Hart 1, V . Ramani 1, M.D. Brown 1, 
N.W. Clarke 3
1 The Paterson Institute, Christie Hospital NHS Trust, Manchester, 
United Kingdom, 2AstraZeneca, Alderley Park, Maccelsﬁ  eld,
Cheshire, United Kingdom, 3 Hope Hospital, Salford, United Kingdom
Prostate cancer is the most common malignancy in men with a predilection 
to metastasise to the bone.  There is a need for a chemotherapeutic agent 
capable of preventing or slowing down the growth of bone metastases. 
AZD3409 is a novel protein prenyl transferase inhibitor with anticancer 
potential.  Methods: The effect of escalating  doses of AZD3409 on 
proliferation of the malignant PC-3 and LNCaP, and non-malignant 
PNT2-C2 prostate epithelial cell lines was determined by CASY TT cell 
counter.  PC-3 and PNT2-C2 colony growth and formation was studied 
in co-culture using long-term human bone marrow stroma harvested from 
individuals with benign disease using standardized quantitative techniques 
in the presence of escalating doses of AZD3409.  Prostatic cellular invasion 
through matrigel (synthetic basement membrane) and cultured endothelial 
monolayers was measured in invasion chambers in the presence and absence 
of drug using cytokeratin labelled quantitation of migrating cells. Results: 
AZD3409 displayed marked anti-proliferative properties on all the non-
malignant (PNT2-C2) and malignant (PC-3 and LNCaP) prostate epithelial 
cells (IC50=10 nM after 5 days exposure).  AZD3409 inhibited invasion 
through bone marrow endothelium towards bone marrow stroma, with a 
concentration of 1000µM inhibiting 50% of PC-3 invasion.  Pre-treatment 
resulted in a 1000-fold decrease in the invasion IC50 with inhibition of 
invasion occurring at 1 nM, levels known to be attainable in vivo.  AZD3409 
inhibited colony formation in bone marrow stroma co-cultures resulting in 
reduced numbers of colonies (50% inhibition at 4 µM) and a reduction in 
colony size (50% reduction at 8 µM).  Conclusion: AZD3409 is a potent 
inhibitor of prostate epithelial cell proliferation and its anti-colony formation 
in bone marrow stroma co-culture suggests potential as an anti-metastatic 
agent. Moreover, AZD3409 shows signiﬁ  cant inhibition of prostate cancer 
cell invasion through human bone marrow endothelium.
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ACTIVITY OF MDI-301, A NOVEL SYNTHETIC RETINOID, 
AGAINST BREAST CANCER IN VIVO
MVCL Appleyard 1, MA O’Neill 1, KE Murray 1, SE Bray 1,
GA Thomson 1, W Purcell 2, AM Thompson 1
1 Ninewells Hospital - University of Dundee, Dundee, United 
Kingdom, 2 Molecular Design International, Inc(MDI), Memphis, 
United States
Natural and synthetic retinoids are known to elicit antiproliferative actions 
in many cancer cells including breast, gastric and ovarian cancers, and 
neuroblastoma. However, the erythema and skin irritation induced by 
such compounds limit their use as therapeutic agents. MDI-301 is a 
synthetic retinoid in which an ester linkage replaces the carboxylic acid 
of 9-cis retinoic acid. It has recently been shown that MDI-301 stimulates 
epidermal and dermal thickening following systemic or topical application 
with no irritation to the skin of hairless mice. The efﬁ  cacy of MDI-301 
was investigated against established MCF7 (ER-positive, high expression 
of Retinoic Acid Receptor-Alpha) and MDA-MB-231 (ER-negative, low 
expression of Retinoic Acid Receptor-Alpha) breast cancer xenografts. 
METHODS: Nunu mice where injected subcutaneously with MCF7 or
MDA-MB-231 cells. After tumour development mice were divided into 3
groups: 1: untreated; 2: vehicle control (DMSO + PBS)  and 3: MDI-301
in DMSO + PBS at 10 mg/kg  for 14 days by the intraperitoneal route.
RESULTS: Mice bearing MCF7 tumours and receiving vehicle alone
had a mean increase in tumour volume of 500% (± 116) after 14 days
and a doubling time of 6 days; mice treated with MDI-301 exhibited a
mean increase of 260% (±100) in tumour volume after 14 days and a
doubling time of 9 days. This corresponds to a signiﬁ  cant reduction in
tumour growth of 48% (Student’s t-test p < 0.05). MDI-301 showed no
antiproliferative effect against MDA-MB-231 xenografts. There was no
weight-loss or signs of toxicity in the treated group.
CONCLUSION: The efﬁ  cacy of MDI-301 in inhibiting in vivo the
growth of MCF7 tumours without evidence of irritation or toxicity
makes this drug a novel candidate for breast cancer therapy.
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BISPHOSPHONATES INDUCE APOPTOSIS AND INHIBIT
ADHESION TO MINERALISED BONE MATRIX IN HUMAN LUNG
CARCINOMA CELL LINES
CD Macdonald, LM Pickering, JL Mansi, KW Colston
St. George’s Hospital Medical School, London, United Kingdom
Lung carcinoma frequently metastasises to bone causing a substantial
clinical problem. Bisphosphonates (BPs) limit the progression of bone
metastases in several cancers, including lung cancer. The mechanisms
involved are not fully understood but BPs are known to have direct
effects  in  cancer  cells in  vitro,  including apoptosis  induction and 
inhibition of invasive properties. Little data exist addressing the effects
of BPs in lung cancer cells; we therefore investigated the consequences
of BP treatment for lung cancer cell survival and adhesion.
Two nitrogen-containing BPs zoledronic acid (ZOL) and pamidronate
(APD) and the non nitrogen-containing compound clodronate (CLOD)
were tested against lung cancer cell lines (n=3). Cell viability and 
number were determined by MTS dye reduction and Sulforhodamine
B assay. Apoptosis was assessed by Cell Death ELISA. Cleavage of 
Ac-DEVD-pNA was used to determine caspase activation. Inhibition
experiments were performed with the caspase inhibitor Z-VAD-FMK.
The effects of ZOL on adhesion were assessed by seeding equal
numbers of viable cells onto dentine matrix for 24 hours. Adherent cells
were washed, ﬁ  xed, stained and counted. 
BPs reduced cell v iability and number  in a concentration and t ime
dependent manner. ZOL and APD were consistently more potent than
CLOD. All BPs induced apoptosis by day three of treatment and this
was associated with caspase activation to varying degrees. BP-induced 
loss of cell viability was partially abrogated by co-incubation with Z-
VAD-FMK. Exposure to 1 or 100 microM ZOL for 24 hours led to a
substantial reduction in adhesion to mineralised dentine, whereas 100
microM EDTA had minimal effect.
This study demonstrates that BPs directly induce apoptosis in human
lung carcinoma cells by both caspase dependent and independent means
and inhibit their adhesion to mineralised dentine. These observations
provide a scientiﬁ  c basis for the clinical effects of BPs in lung cancer.
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HSABODIES: A NEW CLASS OF ENGINEERED
ANTIBODY-BASED MOLECULES FOR TARGETING CANCER 
A Huhalov 1, C Graff 2, KD Wittrup 2, B Tolner 1, Pedley RB 1,
W Vervecken 3, R Contreras 3, RHJ Begent 1, KA Chester 1
1 United Kingdom, Royal Free & University College Medical School, 
London, 2 United Kingdom, Massachusetts Institute of Technology, 
Cambridge, 3 United States, Ghent University, Gent-Zwijnaarde
It was hypothesised that a human antibody-based molecule which had
a long residence time in tumour and a controllable systemic clearance
would be a superior cancer targeting agent in terms of immunogenicity,
tumour uptake and tumour:normal tissue ratios. To test this, a novel
fusion protein was engineered incorporating human serum albumin
(HSA) as a backbone to genetically link two high afﬁ  nity, humanised
derivatives of the anti-carcinoembryonic antigen (CEA) single chain
Fv antibody  fragment MFE-23. Asn-linked g lycosylation sites were
engineered into the HSA linker to modulate its pharmacokinetics by
directing clearance through mannose receptors. The divalent MFE-23-
HSA assemblies, termed HSAbodies, were expressed in Pichia pastoris
by fermentation and puriﬁ  ed  using immobilised metal- and CEA-
afﬁ  nity chromatography. BIACore analysis indicated that the puriﬁ  ed
proteins were functionally divalent in terms of CEA binding.
In vivo studies demonstrated that the 125Iodine-radiolabelled HSAbodies 
speciﬁ  cally localised to LS174T human colon carcinoma xenografts 
whilst clearing rapidly from normal tissues. Overall tumour uptake for the 
unglycosylated HSAbody reached maximum levels of 24.5±12.5% injected 
dose (ID)/g tissue at 24 h following injection, with a corresponding tumour: 
blood ratio of 7:1. The presence of mannose glycosylation on the HSAbody 
resulted in its accelerated systemic clearance compared to the unmodiﬁ  ed 
protein, with subsequently less overall uptake in the tumour (3.5±2.5% 
ID/g at 24 h) but a substantial increase in tumour: blood ratios, with levels 
reaching up to 22:1 at 24 h and as high as 92:1 at 48 h. 
A novel class of CEA-targeting molecules has been described which
combines molecular design features such as humanisation, high afﬁ  nity
and avidity to achieve long tumour retention and optional circulating
half-life.  These features indicate a clear therapeutic and diagnostic
potential for HSAbodies in both native and glycosylated form.
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ENHANCED IN VIVO SELECTION OF RETROVIRALLY 
TRANSDUCED HAEMOPOIETIC STEM CELLS USING HOXB4 
AND MGMT
MD Milsom, LB Woolford, D Gagen, LJ Fairbairn
United Kingdom, Paterson Institute for Cancer Research, Manchester
Recent clinical trials in haemopoietic cell gene therapy have highlighted 
the importance of an in vivoselective advantage in achieving therapeutic
levels of gene-modiﬁ  ed cells. We have developed a tri-cistronic vector 
that co-expresses HoxB4 with the drug-resistance factor MGMT and 
eGFP. Using an in vivo competitive repolulation/selection assay, we
have demonstrated that this vector confers a profound engraftment
advantage on transduced haemopoietic stem cells, which is further 
ampliﬁ  ed following application of an in vivo selection pressure using
an O6-alkylating a gent. However, we have also shown that over-
expression of HoxB4 in a multi-potent haemopoietic cell line leads
to a delay in myeloid and erythroid differentiation – a potential step
towards transformation. To reduce this risk, we have developed a drug-
inducible form of HoxB4 who’s activity is dependent on tamoxifen
and have shown that this confers a tamoxifen-dependent advantage to
haemopietic stem cells both in vitro and in vivo. This combination of a
powerful, inducible selective advantage with efﬁ  cient expression via tri-
cistronic vectors may allow the development of safer and more effective
gene therapy strategies.
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SYNTHESIS AND ANALYSIS OF SPIRUCHOSTATIN A, A
POTENT BICYCLIC TETRAPEPTIDE HISTONE DEACETYLASE
INHIBITOR
G Packham 1, A Yurek-George 2, F Habens 1, M Brimmell 1, A Ganesan2
1 United Kingdom, Cancer Research UK Oncology Unit, University of 
Southampton School of Medicine, Southampton, 2 United Kingdom,
School of Chemistry, University of Southampton, Southampton
There is considerable excitement that histone deacetylase inhibitors
(HDACi) may be a very important new class of anti-cancer drugs,
inducing growth arrest and apoptosis in a wide range of cancer cells with
relatively little effect on normal cells.  FK-228, a bicyclic tetrapeptide with
potent HDACi activity, has produced encouraging results in clinical trials.
FK-228  functions as a natural pro-drug and unlike most other HDACi,
possesses some selectivity versus individual HDAC enzymes.  Therefore,
the further development of this class of compounds is of major importance.
However, since FK-228 is a natural product isolated by fermentation, it is
unlikely to be optimal for inhibiting human HDACs and has not been
amenable for structural modiﬁ  cation.  We have now developed a novel
synthetic route for Spiruchostatin A, a recently isolated natural product
resembling FK-228.  We have demonstrated that Spiruchostatin A is a
bona ﬁ  de HDACi since, similar to trichostatin A, it induced accumulation
of acetylated histones and activated the p21cip1 promoter (a well studied
HDACi-inducible promoter) in MCF7 breast cancer cells. Moreover,
Spiruchostatin A inhibited the growth of MCF7 cells at approx. ten-fold
lower concentrations than TSA (IC50 for growth inhibition of 10 nM and
100 nM for Spiruchostatin A and TSA, respectively).  We also synthesised
an analogue of Spiruchostatin A, epimeric at the beta-hydroxy acid
fragment.  By altering the stereochemistry at this position, the potential
interactions of  the tetrapeptide “cap” of Spiruchostatin A with amino-
acids surrounding the active site of the target enzyme would be radically
altered.  Consistent with the idea that the “cap” structure is an important
determinant for HDAC binding, epi-Spiruchostatin A did not inhibit the
growth of cancer cells and does not activate the p21 promoter.
Posters
S63
British Journal of Cancer (2004) 91(Suppl1), S24–S80 & 2004 Cancer Research UKP130:3
OLIGOSACCHARIDE DERIVATIVES OF LOW-MOLECULAR WEIGHT
HEPARIN AS ANGIOGENESIS INHIBITORS
J Hasan 1, S.D Shnyder 2, M Bibby 2, A Clamp 1, R Byers 3, G.C. Jayson 1
1 United Kingdom, Paterson Institute for cancer research/ Christie Hospital,
Manchester, 2 United Kingdom, Cancer research unit,Univerist of bradford,
Bradford, 3 United Kingdom, University of Manchester, Manchester
The aim of this study was to deﬁ  ne the anti-angiogenic activity of length-deﬁ  ned 
oligosaccharide derivatives of low-molecular weight heparin in a novel in vivo model of 
angiogenesis, the hollow ﬁ  bre assay. Hollow ﬁ  bres are made of polyvinylidene ﬂ  uoride
with an internal diameter of 1mm and a molecular weight cutoff of 500,000 Da. This
allows pro-angiogenic growth factors produced by cells within the ﬁ  bres to migrate and 
stimulate angiogenesis in surrounding tissues whilst cells themselves are retained within 
the ﬁ  bre. Heparan sulfate oligosaccharides were obtained by partial depolymerisation of 
Innohep (tinzaparin sodium) using heparinase I. Oligosaccharides ranging in size from 
hexasaccharides to tetradecasaccharides (dp 6-dp14) were used. Hollow ﬁ  bres measuring 
1.5cm in length were set up using freshly harvested H460 non-small cell lung carcinoma 
cells (NSCLC) at a seeding density of 2.5 x 105cell/ml. This cell line elaborates a host 
of pro-angiogenic growth factors, principally VEGF. Under light inhalation anaesthesia,
one hollow ﬁ  bre was implanted subcutaneously in the lower left dorsal area and one ﬁ  bre
in the lower right dorsal area of male B+K nude mice using the small tumour implant 
trocar (day0). Oligosaccharides (20mg/kg) were administered intraperitoneally between 
day 1 and day 23. The animals were sacriﬁ  ced and ﬁ  bres harvested on the day following 
the last injection. The treatment groups were as follows (5 animals per group):
Dp6 (20mg/kg/day)
Dp 8 (20mg/kg/day)
Dp 10 (20mg/kg/day)
Dp12 (20mg/kg/day)
Dp 14 (20mg/kg/day)
Untreated control groups: (a) ﬁ  bres + cells (Positive control)
                                         (b) Fibres + medium only (Negative control)
An MTT assay was performed on one ﬁ  bre per animal to conﬁ  rm adequate cell
viability. Parafﬁ  n-embedded sections were stained with a pan-endothelial marker 
(von Willebrand factor) and neoangiogenesis quantiﬁ  ed by manual microvessel
counting (x400 magniﬁ  cation). Microvessels were counted in the new granulation
tissue that envelopes the hollow ﬁ  bre. Microvessel counts were performed by a
single observer in a blinded fashion to minimise bias. Of the oligosaccharides
tested (dp6-dp14), the octasaccharides (dp8s) signiﬁ  cantly inhibited angiogenesis
compared to the untreated control (point estimate 0.56, 95%CI 0.34-0.94).
Conclusion: The shorter length oligosaccharide derivatives of Tinzaparin,
principally octasaccharides, inhibit the pro-angiogenic activity of a H460 NSCLC
cell line in vivo and could be potentially developed as anti-angiogenic agents.
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OSTEOPONTIN (OPN) IS DIFFERENTIALLY ACTIVATED 
BY TWO LOW-CALCEMIC ANALOGS OF 1α,25-
DIHYDROXYVITAMIN D3 (VD3) BUT INHIBITED BY TCF-4.
M McCann 1, M El-Tanani 1, G Posner 2, F.C Campbell 1
1 United Kingdom, Surgery, Cancer Centre, The Queen’s University of 
Belfast, Belfast, 2 United Kingdom, Dept of Chemistry, Faculty of Arts
and Sciences, Johns Hopkins, Baltimore
Introduction:  Osteopontin (OPN) is implicated in colorectal cancer
invasion and metastasis. Regulation of OPN transcription may be
important for CRC prevention. Ligand activated nuclear vitamin D
receptor (nVDR) binds to the response element (VDRE) of the OPN
promoter and may have indirect effects on OPN transcription through
the β-catenin/Tcf-4/Lef-1 pathway.
Aim:  This study tests the hypotheses that (i) low-calcemic analogs of 
vitamin D3 activate OPN transcription in proportion to their VDR-mediated 
transcriptional potencies and (ii) components of the β-catenin/Tcf-4/Lef-1 
pathway inﬂ  uence ligand-nVDR activated OPN transcription.
Methods:  Rama 37 cells were transiently transfected with an OPN 
promoter-luciferase reporter construct with or without human nuclear VDR 
(hnVDR) cDNA, before treatment with either VD3, high activity (QW) or 
low activity (BTW) low-calcemic VD3 analogs, across a dose range. Cells 
were then co-transfected with β-catenin, Tcf-4, Lef-1 or a combination of 
their cDNAs and the effects on OPN transcription were assessed.
Results:OPN transcription was induced by >50 fold by QW 10-9M vs
BTW 10-7M (vs VD3 [10-8M]). Transfection of cells with β-catenin and
Lef-1 cDNAs, enhanced OPN transcription. Conversely, Tcf-4 strongly
inhibited spontaneous or VD3 stimulated OPN transcription (eg OPN +
hnVDR + VD3 10-8M vs OPN + hnVDR + VD3 10-8M +Tcf-4 =110 vs
24.7 RFU’s).  
Conclusions: Low-calcemic analogs QW and BTW activate OPN
transcription  in  proportion to their VDR-mediated transcriptional
activities. Tcf-4, a component of the nVDR responsive β-catenin/Tcf-
4/Lef-1 pathway,  inhibits  ligand-nVDR activated OPN transcription.
These molecular mechanisms may provide novel therapeutic targets for
CRC prevention.
P130:5
CYCLOPHOSPHAMIDE INDUCED CD11B+ CELLS CAN INHIBIT 
ANTI-CD40 MONOCLONAL ANTIBODY THERAPY OF B-CELL
LYMPHOMA
J Honeychurch, M J Glennie, T M Illidge 
United Kingdom, Cancer Sciences Division, Southampton University,
Southampton
Immunotherapy is emerging as a promising strategy for the treatment
of B-cell lymphoma. Some immunomodulatory monoclonal antibodies
(mAb) such as anti-CD40, have shown signiﬁ  cant activity in pre-clinical
models. Evidence is emerging to suggest that by combining these mAb
with conventional treatments, such as chemotherapy, the anti-tumour 
effects may be further enhanced. Here, we have assessed the efﬁ  cacy
of combining anti-CD40 mAb with the commonly used cytotoxic drug
cyclophosphamide (CY).
Initially, we conducted a number of  immunotherapies against the well 
established BCL1 lymphoma model. As anti-CD40 mAb can be therapeutic 
alone, we used sub-optimal  doses of t he mAb to look  for possible 
synergistic effects. Interestingly, timing of CY relative to mAb appeared 
critical to therapeutic outcome. Cohorts given CY 7 days prior to anti-CD40 
(d7 CY) show reduced survival compared to those receiving mAb alone, 
whereas treatment with CY 1 day before, or on the same day as mAb results 
in increased survival. In vivo tracking experiments revealed that around 5 
days after anti-CD40 treatment there is a potent CTL response that clears 
tumour. However, d7 CY therapy results in reduced CTL expansion but an 
increased number of splenic CD11b+ cells compared to other treatments.  +
These CD11b+ cells have an immature myeloid precursor phenotype and  +
are able to produce nitric oxide (NO). Co-culture of CD11b+ cells with  +
murine splenocytes results in greatly reduced CTL proliferation, but not 
apoptosis, that can be reversed in the presence of NO inhibitors. Similarly, 
splenic CTL proliferation in vivo is inhibited by this increased population 
of CD11b+ cells and adoptive transfer of puriﬁ  ed CY induced CD11b+ in to 
non-CY treated mice inhibits anti-CD40 therapy of BCL1. 
This data indicates that combining CY with immunotherapy can enhance
therapeutic responses, but the timing of CY relative to immunotherapy
is critical to therapeutic outcome.
P130:6
DETERMINATION OF ONDANSETRON IN PLASMA AND ITS 
PHARMACOKINETICS FROM CANCER PATIENTS AFTER 
CHEMOTHERAPY
J Yu, C.J Ward, S Brown, C.R. Wolf, E.M. Rankin
United Kingdom, University of dundee, Dundee
Ondansetron is an antiemetic widely prescribed to patients undergoing
chemotherapy. Side effects include constipation, nausea, vomiting and
headache. As partly ongoing study into inter-individual variability
in pharmacokinetics from cancer patients, we developed a high
performance liquid chromatography-tandem electrospray mass
spectrometric assay for quantiﬁ  cation of ondansetron in plasma from
cancer patients.undergoing chemotherapy. The liquid chromatographic
separation was achieved on a phenyl column with a gradient mobile
phase of aqueous 20 mM ammonium acetate-acetonitrile at a ﬂ  ow rate
of 0.2 ml/min. The assay was validated between 1.0 to 200 ng/ml with
tropisetron as the internal standard. The intra- and inter-day precision
did not exceed 12.5% and 11.1% respectively. The intra- and inter-
day accuracy did not exceed 16.5% and 6.8% at ﬁ  ve different quality
control samples (1.0, 2.5, 25, 150 and 200ng/ml). The Application of the
assay to determine pharmacokinetics of ondansetron in cancer patients
receiving chemotherapy is described.
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ANALYSIS OF THE ROLE OF THE MDM2-P53 PATHWAY IN
TUMOUR EVOLUTION IN RENAL CELL CARCINOMA
HE Warburton 1, KF Parsons 1, MW Linehan 2, MT Boyd 1
1 United Kingdom, University of Liverpool, Department of Surgery, 
Liverpool, 2 United Kingdom, National Cancer Institute, Urologic 
Oncology Branch, Bethesda
A major obstacle to the management of renal cell carcinoma (RCC) is the 
paucity of reliable prognostic indicators. Two lines of evidence support the 
conclusion that the MDM2-p53 pathway might provide such an indicator. 
Firstly a survey of 120 cases of RCC found that high levels of p53 and 
MDM2 frequently occur in renal cell carcinoma (19% of patients) and that 
this phenotype has the poorest prognosis with a mean disease free survival 
time of 0.8 years c.f. >5 years in patients with low or undetectable p53 and 
MDM2. Secondly, MDM2 is located on 12q13 and gain of 12q has been 
found to be one of the strongest predictors of poor prognosis.
We examined the level of MDM2 protein, RNA and DNA in a panel of 
11 RCC cell lines. We have found that 5/11 of the RCC cell lines express
higher levels of MDM2 protein than U2OS osteosarcoma cells. This
occurs in the absence of MDM2 ampliﬁ  cation or transcriptional up-
regulation. It has previously been found that MDM2 protein can be up-
regulated by a process of enhanced translation and we are investigating
this and also the stability of the MDM2 protein.
Given the pattern of mutations described above, it is unlikely that MDM2 up-
regulation arises prior to p53 mutation/LOH. In cell lines, over-expression 
of MDM2 is not generally achievable by stable transfection, because of 
ill-deﬁ  ned toxicity associated with MDM2 expression. Thus we suggest, 
that in RCC (similar to bladder cancer) acquisition of MDM2 up-regulation 
confers an advantage to RCC cells promoting an aggressive phenotype but 
this only occurs in p53 mutant cells. We have introduced both MDM2 and 
a dominant negative p53 mutant into RCC cells that possess low levels of 
MDM2 protein and wt p53 either: MDM2 ﬁ  rst, p53 second or vice versa 
to mimic apparent tumour evolution. We have examined the cells’ viability 
and proliferation to determine whether RCC cells can tolerate high levels of 
MDM2 only in the presence of mutant p53.
P132
A POTENTIAL ROLE FOR THE E7 PROTEIN OF HIGH RISK 
HUMAN PAPILLOMAVIRUSES IN IMMUNE EVASION
G Bottley, GE Blair 
United Kingdom, University of Leeds, Leeds
Many human viruses encode proteins that enable infected cells to evade
the actions of the cellular immune system. Similarly, most human tumour
cells show down-regulation of the major histocompatibility complex
(MHC) class I pathway of antigen processing and presentation, thus
resulting in an escape from immunosurveillance by cytotoxic T cells.
Human Papillomaviruses (HPV) of the high risk group (such as HPV
16,18 and 31) cause a range of ano-genital cancers (for example cervical
cancer) and are the most signiﬁ  cant virally-induced human cancers.
We have been investigating the role of the E7 protein from the high
risk HPV in antigen processing and presentation. Previous studies
have suggested that expression of E7 results in transcriptional down-
regulation of MHC class I. However, this needs to be extended by
analysing any functional change in antigen processing that is directly
attributable to the E7 protein. It has proved difﬁ  cult to examine the role
of E7 alone, as E7 has pro-apoptotic activity, normally countered by the
viral E6 protein.
Recent advances have allowed two new approaches to this problem.
Inhibition of E7 translation with speciﬁ  c  small  interfering RNA
(siRNA) is able to “knock out” E7 expression in HPV 16-transformed
cell lines and it is then possible to examine antigen processing in these
cells. Inhibition of E7 expression has conﬁ   rmed that cells enter a
replicative senescent state, with an associated G1 arrest. These cells also
appear to subtly modulate their antigen processing pathways, although
it is not yet clear whether this is a direct effect of loss of E7 or linked
to the senescent state of the cells. Another approach that we have taken
is the use of cell lines stably transfected with a plasmid construct in
which an inducible promoter is linked to the HPV 16 E7 gene. Removal
of Tetracycline from the culture medium results in expression of E7.
Current studies are directed towards analysis of MHC class I expression
in both experimental systems.
P133
SIRNA-MEDIATED DEPLETION OF FGFR1 INHIBITS
BFGF-INDUCED APOPTOSIS IN CELLS OF THE EWING’S 
SARCOMA FAMILY OF TUMOURS (ESFT)
JR Boyne, SA Burchill, Candlelighter’s Research Laboratory,
Leeds
Treatment of the ESFT cell line TC-32 with basic ﬁ  broblast growth
factor (bFGF) leads to cell death through a caspase-8 and 3 dependent
mechanism which is accompanied by an up-regulation of p75NTR
(Westwood et al, 2002, Oncogene, 21(5): 809-824). In this study we
have investigated the role played by FGFR1 signalling in the initiation
of bFGF-induced cell death.
  Viable cell number was quantiﬁ  ed using the trypan blue exclusion
assay and apoptosis by ﬂ  uorescent associated cell sorting (FACS) of 
annexin V/PI labelled cells. Total and phosphorylated FGFR1, ERK 
and p38MAPK were analysed by Western blot. FGFR phosphorylation was K
inhibited using the small molecule SU5402 (Merck Biosciences), and 
FGFR1 expression depleted using siRNA. 
  bFGF (20ng/ml) induced phosphorylation of FGFR1 in TC-32
cells after 2 minutes exposure. This was accompanied by a sustained 
activation of Ras/ERK and p38MAPK. Pre-treatment of TC-32 cells
with SU5402 (20µM) rescued 92% of cells from bFGF-induced cell
death, consistent with the hypothesis that bFGF-induced cell death
is mediated through an FGFR dependent pathway. SU5402 inhibited 
phosphorylation of ERK/p38MAPK and the up-regulation of p75 K NTR.
  FGFR1 was depleted at the mRNA level using siRNA. Speciﬁ  c
depletion of FGFR1 was conﬁ  rmed by real-time PCR. Western blot
analysis demonstrated that FGFR1 was depleted at the protein level
compared to a scramble siRNA control. Depletion of FGFR1 in TC-32
cells prevented up-regulation of p75NTR and inhibited bFGF-induced cell R
death (100%).  
 In summary, bFGF-induced cell death in the ESFT cell line TC-32
requires functional FGFR1 signalling.
P134
DEFINING POTENTIAL TARGETS FOR CELL-BASED 
IMMUNOTHERAPY OF COLORECTAL CANCER
SE Perry, GP Cook, AA Melcher, P Quirke, GE Blair 
University of Leeds, Leeds, United Kingdom
Despite signiﬁ  cant advances in surgery, radiotherapy and chemotherapy,
cure rates for colorectal cancer (CRC) remain low and novel approaches
to treatment are urgently needed. Immunotherapy holds great promise
for cancer therapy, if suitable targets can be identiﬁ  ed. We are therefore
exploiting the results of microarray analysis to identify target proteins
that are signiﬁ  cantly up-regulated in CRC and contain T cell epitopes. We
are currently evaluating several proteins for their potential in cell based
immunotherapy. Here we describe data on one such protein, CDCP1 (a
Cub Domain Containing Protein), a cell-surface molecule identiﬁ  ed by
its elevated expression in colorectal cancer tissues. We have used ﬂ  ow
cytometry to determine expression levels in a panel of human colorectal
and other tumour cell lines as well as primary ﬁ  broblasts, endothelial
and peripheral blood mononuclear cells. Expression was not detected
in normal human cells but extensive variation in surface expression of
CDCP1 was noted among colorectal and gastric cell lines. In addition,
very high levels of expression were found in cervical carcinoma cell
lines.  These results were conﬁ  rmed by real-time RT-PCR and Western
blotting. We are extending these expression studies to include other
primary cell types and staged colorectal tumour samples. However the
high expression levels on cells derived from several tumour cell types
suggest that CDCP1 may represent a novel target for T cell-mediated
immunotherapy. The variations noted in CDCP1 expression between
different colorectal cell lines highlight the importance of targeting
particular immunotherapeutic strategies to selected groups of patients.
 CDCP1 that may be derived from two differentially-spliced transcripts.
Furthermore there is evidence that CDCP1 can be cleaved into at
least two.
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BFGF-INDUCED APOPTOSIS OF ESFT CELLS IS EFFECTED
THROUGH SUSTAINED ACTIVATION OF P38MAPKAND K
UP-REGULATION OF P75NTR
AJK Williamson, JR Boyne, BC Dibling, SA Burchill
Cancer Research UK, St. James’s Hospital, Leeds, United Kingdom
In this study the potential role of the mitogen activated protein kinases’s
c-Jun N-terminal kinase (JNK), extracellular-regulated kinase (ERK)
and p38MAPK in bFGF-induced cell death of the Ewing’s sarcoma family K
of tumours (ESFT) has been investigated. The ESFT cell lines TC-32,
TTC-466, A673 and the neuroblastoma cell line SK-N-SH were studied.
Viable cell number was quantiﬁ  ed using the trypan blue exclusion assay
and apoptosis by ﬂ  uorescent associated cell sorting (FACS) of annexin
V/PI labelled cells. Total and phosphorylated JNK, ERK, p38MAPK and  K
p75NTR were analysed by ELISA and Western blot. bFGF induced cell R
death in a time dependent manner in TC-32 and TTC-466, but not
in A673 and SK-N-SH cells. Exposure of TC-32 and TTC-466 cells
to bFGF induced rapid and sustained phosphorylation of ERK and 
p38MAPK; phosphorylation was detected ﬁ  ve minutes after addition of 
bFGF and was sustained for up to 2 h. Pre-incubation with PD98059
(10µM) inhibited ERK activation and rescued approximately 30% of 
TC-32 cells from bFGF-induced cell death. However inhibition of 
p38MAPK signalling with SB202190 (20 K µM) rescued 100% of TC-32
cells from bFGF-induced cell death. In contrast ERK and p38MAPK were K
transiently activated in TC-32 cells treated with the stem cell factor, and 
in SK-N-SH cells in which bFGF-induced proliferation. However in
A673 cells that do not die in response to bFGF p38MAPK was transiently K
activated, whereas ERK activation was sustained. JNK was transiently
activated in all cells, independent of their response to bFGF. Induction
of cell death in ESFT cells after exposure to bFGF was associated with
an up-regulation of p75NTR expression; knock out of p75 R NTR with RNAi R
rescued cells from bFGF-induced cell death. Inhibition of p38MAPK 
signalling with SB202190 (20µM) prevented up-regulation of p75NTR.
Induction of cell death by bFGF appears to be mediated by p38MAPK-
dependent up-regulation of p75NTR.
P136
EXPRESSION AND EXPLOITATION OF NEURAL-SPECIFIC
STATHMINS IN LUNG CANCER
F Aladin 1, E Bennett 2, G Sunderland 1, N Mori 4, N Blake 3, J Coulson1
1 Physiological Laboratory, University of Liverpool, Liverpool, 
United Kingdom, 2 Human Anatomy and Cell Biology, University 
of Liverpool, Liverpool, United Kingdom, 3 Medical Microbiology, 
University of Liverpool, Liverpool, United Kingdom, 4 National
Institute for Longevity Sciences, Aichi, Japan
Stathmin proteins  destabilise microtubules  during cell  division or neurite
outgrowth. Stathmin 1 is ubiquitous, whereas Stathmin 2 (SCG10), Stathmin 
3 (SCLIP) and Stathmin 4 (RB3) exhibit degrees of neural-speciﬁ  city.  SCG10
expression is repressed by the neuron restrictive silencer factor (NRSF) in non-
neuronal cells through association with co-factors including histone deacetylase 
(HDAC) and MeCP2. Small cell  lung cancer (SCLC)  is characterised  by 
expression of neuroendocrine and neural-restricted genes, and we have described 
an isoform of NRSF that dysregulates transcriptional repression in SCLC. We
now report that stathmin 1 and the neural-speciﬁ  c stathmins are highly expressed 
in neuroendocrine SCLC. In particular, SCG10 was detected in 8/8 SCLC, 0/4
non-SCLC (NSCLC) and 0/2 normal bronchial epithelial cell lines by RT-PCR.   
The SCG10 protein was also seen in SCLC cell lines by western blotting and 
immunocytochemistry. A heterologous SCG10 reporter construct demonstrated 
highly differential expression between SCLC and NSCLC lines.  SCLC-speciﬁ  c 
expression was repressed by overexpression of NRSF whereas, in NSCLC, the
HDAC inhibitor trichostatin A (TSA) de-repressed expression.  Transcription of 
stathmin 1, RB3 and SCLIP is less well characterised, but may also be regulated 
by NRSF. We therefore investigated the role of HDAC and methylation in 
lung cells using TSA and 5’-aza-cytidine (5AzaC).  In untreated NSCLC, the
expression of endogenous stathmins was low or undetectable by RT-PCR, but 
was increased by treatment with TSA or 5AzaC.  As the SCG10 transcript was
highly selective for SCLC, this may represent a tumour-speciﬁ  c promoter for 
viral-directed molecular therapy.  Infection of various cell types with adenoviral 
vectors showed that expression of EGFP dependent on the SCG10 promoter was
speciﬁ  c to neuroendocrine tumour cells and was actively restricted in other cell 
lines by HDAC.   Our data suggest the neural-speciﬁ  c stathmins play a role in 
SCLC and may be exploited in detection or treatment of this disease.
P137
THE MORPHOGENIC PROPERTIES OF OLIGOMERIC
COLLAGEN XVIII-DERIVED ENDOSTATIN ARE DEPENDENT
ON CELL SURFACE GLYCOSAMINOGLYCANS
AR Clamp 1, FH Blackhall 1, A Henrioud 1, GC Jayson 1,
K Javaherian2, JT Gallagher 1, CLR Merry 1
1 Cancer Research UK and University of Manchester Dept of Medical
Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom,
2 Department of Surgery, Children’s Hospital, Harvard Medical School,
Boston, United States
Monomeric endostatin (EM) is well-known for its anti-angiogenic properties.
In contrast, oligomeric endostatin generated from the intact C-terminal domain 
of collagen XVIII (ED) induces a promigratory phenotype in endothelial cells
which is inhibited by its monomeric counterpart (Kuo et al 2001 J Cell Biol 
152:1233). Many pro- and anti-angiogenic growth factors require cell surface
glycosaminoglycans  (GAG)  for their  bioactivity and a lthough endostatin  is
heparin-binding, the role of GAGs in regulating the activity of EM/ED is unclear.
In this study we have shown that exogenous glycosaminoglycans can substitute 
for EM and inhibit the promigratory action of ED in a Matrigel angiogenesis 
assay. This property is size-dependent as heparin-derived oligosaccharides 
containing more than 20 monosaccharide residues were optimal inhibitors.
ED was also shown to induce marked morphological changes in Chinese
Hamster Ovary cells  (CHO)- an epithelial cell  line, plated on Matrigel.
This novel observation allowed use of a panel of CHO mutants with
deﬁ  ned GAG biosynthetic defects. The morphogenic properties of ED were
demonstrated to be absolutely dependent on the presence of cell- surface
GAG, with heparan sulphate necessary for the wild-type phenotype. Heparan
sulphate 2-O-sulphation is not required as CHO pgsF-17 which lack 2-O-
sulphotransferase activity respond normally to ED stimulation.
The use of zero-length cross-linking techniques (Grabarek and Gergely  1990
Anal Biochem 185:131) showed that multiple EM molecules can bind to a 
single oligosaccharide chain simultaneously. This indicates that one potential
anti-angiogenic mechanism of EM is to block the GAG-binding sites of ED.
This study demonstrates the importance of cell surface GAG binding for the
activity of ED and  suggests that the activity of ED/EM may not be speciﬁ  c
to endothelial cells.
P138
CYTOKINE MEDIATED MODULATION OF THE MYC 
NETWORK IN BARRETT’S METAPLASIA
J. Boult 1, L.S. Young 2, M.J. Campbell 1, C. Tselepis 1
1 Division of Medical Sciences, Univesity of Birmingham, 
Birmingham, United Kingdom, 2 Division of Cancer Studies, 
University of Birmingham, Birmingham, United Kingdom
Barrett’s Metaplasia  (BM)  is a pre-malignant  lesion predisposing to 
oesophageal adenocarcinoma. Progression of BM to adenocarcinoma is 
characterised by sequential molecular and genetic events, driven partly 
by components of the gastro-oesophageal reﬂ   uxate. Supporting this 
hypothesis,  it  has  been  demonstrated t hat  bile acids and c ytokines can 
induce c-myc expression, consistent with the reported over-expression of 
this oncogene during the malignant progression of BM. However, the ability 
of c-myc to act as a transcription factor and to inﬂ  uence cell fate is partly 
governed by levels of the related Mad family proteins, including Mad-1 and 
Mxi-1. This study aims to characterise the levels of c-myc, Mad-1 and Mxi-
1 in reﬂ  ux oesophagitis, BM and oesophageal adenocarcinoma. In addition 
the oesophageal squamous cell line OE21 was used to investigate the effects 
of the cytokines IL-8, IL-1β and IFN-γ on these proteins.  γ
Using Real T ime PCR, we demonstrated a signiﬁ  cant  induction
of c-myc in 5/8 and 5/9 samples of reﬂ   ux oesophagitis and BM,
respectively. In these c-myc positive samples, there was a parallel
induction in Mxi-1. In all the samples which failed to show an elevation
in c-myc or Mxi-1 there was instead a dramatic induction in Mad-1.
Immunohistochemical staining demonstrated that c-myc was localised
to the basal layer of the native squamous oesophagus whilst Mxi-1 was
expressed in the parabasal layer. Both proteins were localised in areas
of intense inﬂ  ammation in specimens of oesophagitis. Utilising OE21
cells we further demonstrated that IL-8 (10ng/ml), IL-1β  (10ng/ml)
and IFN-γ (10ng/ml) failed to induce c-myc protein expression over γ
24 hr. However, Mad-1 protein was suppressed by IL-8 and IL-1β
but dramatically induced by IFN–γ.    –γ.    An understanding of the role of
cytokines in modulating the Myc-Mad network will provide important
insights into factors governing the initiation and malignant progression
of BM and may identify targets for therapeutic intervention.
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LOCALIZATION OF P43/ENDOTHELIAL-MONOCYTE-
ACTIVATING-POLYPEPTIDE-II (P43/EMAP-II) IN NORMAL AND
NEOPLASTIC HUMAN LIVER
W Faisal, P Symonds, JC Murray
Wolfson Digestive Diseases Centre, Queen’s Medical Centre,
Nottingham University, Nottingham, United Kingdom
Aim: First isolated from growth medium conditioned by tumour
cells, we have recently shown that p43/EMAP-II induces apoptosis in
activated lymphocytes, enabling tumour cells to evade immune response
(1). Prolonged immune evasion by hepatitis virus has been linked to
hepatocellular carcinogenesis, though t he mechanism(s)  involved 
are poorly understood. To investigate p43/EMAP-II as a possible
mechanism for virus-induced immunosuppression, we ﬁ  rst studied the
expression of p43/EMAP-II in normal human liver tissue and normal
(THLE-3) and human hepatoma (Alexander cells & HuH-7) cell-line.
Methods: Normal liver tissue samples were obtained through autopsy
from 3 subjects for immunohistochemistry and analysed using image
analysis software. THLE-3 was used for immuno-ﬂ  uorescence
microscopy, while supernatant and cell lysate of all three cell-lines were
used for western blot analysis for the detection of EMAP-II.
Results: In general, hepatocytes in tissue sections showed strong
immunoreactivity  for p43/EMAP-II with a punctuate pattern, while
the Kupffer cells and bile ductules were generally negative. There is
signiﬁ  cant gradual increase in expression of the polypeptide from zone-
1 to zone-3 of hepatic acini (p (p ( <0.005). Immunoﬂ  uorescent microscopy
showed positive peri-nuclear  granular staining o f p43/EMAP-II  in
THLE-3 cells. Western blot analysis revealed that both normal and 
neoplastic hepatocytes contain 34kDa precursor form of p43/EMAP-II,
which is not secreted in the media under normal culture conditions.
Conclusion: The compartmentalized pattern of distribution of p43/EMAP-
II in hepatic acini may be an extension of the physiological property of the 
liver which sequesters more enzymes and cytokines in zone 3 than zone 1, or 
might be a response to differing levels of oxygen tension in different zones. 
An assessment of functional signiﬁ  cance of strong staining of EMAP-II in 
liver and factors regulating its expression is currently underway.
Reference: (1) Murray et al. (2004). J Immunol 172:274.
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P43/EMAP II: ISOLATION AND CHARACTERISATION OF
PUTATIVE RECEPTOR(S)
S Panjwani, YM Heng, JC Murray
Wolfson Digestive Diseases Centre, Queen’s Medical Centre, 
Nottingham University, Nottingham, United Kingdom
P43/EMAP II, a 22 kDa polypeptide, was ﬁ  rst  puriﬁ   ed from the
supernatant of Murine meth A-induced ﬁ  brosarcoma cells. This single-
chain leaderless polypeptide is initially synthesised as 34 kDa intracellular
precursor, associated with the multi-tRNA synthetase complex facilitating
aminoacylation activity. The 34 kDa precursor molecule is proteolytically
cleaved to release the 22 kDa mature polypeptide extracellularly, by an as
yet unidentiﬁ  ed pathway, in a similar manner to the leaderless precursor
of IL-1β. The secreted form of EMAP II acts as a pleotrophic cytokine
with plethora of effects both, in vitro and in vivo on a variety of cell types.
It induces tissue factors on the surface of endothelial cells, increasing the
expression of E- and P- selectins and TNFR1, and attracting monocytes and
neutrophils in vitro. In vivo, it sensitises resistant immunological tumours
to the anti-tumour effects of TNF. It also induces apoptosis in a number
of cell types, including endothelial cells, implying it’s pro-inﬂ  ammatory
and anti-angiogenic effects. According to our recent ﬁ  ndings, EMAP
II inhibits DNA synthesis and cell division, and induces apoptosis in
mitogen-activated  lymphocytes  in PBMC preparations, and  in Jurkat
cells T-cells, suggesting a novel role in immune evasion by eliminating
T-lymphocytes and protecting the tumour cells (1). To facilitate a better
understanding and signiﬁ  cance of the biological role of EMAP II and its
use in cytokine based tumour treatment, we have cloned and puriﬁ  ed
biologically active mature EMAP II with a C-terminal poly-Histidine-tag
to ﬁ  sh out cell-surface receptor(s) from Jurkat cell and PBMC using Ni-
NTA afﬁ  nity chromatography. Our preliminary studies using Jurkat cell
biotinylated membrane preparation show co-localisation of EMAP II with
biotinylated membrane proteins suggesting possible receptors for EMAP
II. We intend to identify and characterise the co-localised proteins and
study their distribution on cell surface and cell types.
(1) Murray et al. (2004). J Immunol 172:274.
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STRUCTURE AND REGULATION OF THE ENDOTHELIAL
MONOCYTE ACTIVATING POLYPEPTIDE II (EMAP-II) GENE
YM Heng, J Edgson, P Symonds, JC Murray 
Wolfson Digestive Diseases Centre, Queen’s Medical Centre, Nottingham
University, Nottingham, United Kingdom
The 34kDa Endothelial Monocyte Activating Polypeptide II (EMAP-II),
ﬁ  rst found in tumor cell supernatants, is believed to be identical to the p43
auxiliary component of the mammalian aminoacyl multisynthetase complex 
(1).  We recently showed that in the tumor environment this protein is a 
highly expressed extracellular molecule that inhibits proliferation and induces
apoptosis in lymphocytes (2). This may constitute a novel immunosuppressive
pathway  in certain tumors.  Aim: We are attempting to understand t he
regulation of EMAP-II expression by studying the structure and regulatory 
regions of t he  gene, as well as the tissue  distribution of  its expression.  
Methods: We searched genome databases, performed 5’ RACE to map
RNA start sites, Northern hybridisations to determine RNA distribution and 
size, and Western blots to determine protein size in hamster and human cell
extracts.  Results: The human EMAP-II gene spans ~30kb and 7 exons,
and is located in a head-to-head orientation with a novel gene HSPC302 on 
chromosome 4q22-25.  The intergenic region ﬂ  anked by the 2 genes showed 
strong bidirectional promoter activity in reporter asays. By Northern analysis,
EMAP-II mRNA was relatively weakly expressed in most normal tissues
examined, but most highly expressed in normal human testis, as 3 different 
transcripts.  All tumour cells examined also exhibit 3 mRNA species, albeit 
in varying ratios.  Using Western blotting techniques, we detected EMAP-
II as a predominant 34kDa protein in human and hamster cells.  However,
hamster appears to also express a minor 43kD form, presumably due to ‘leaky’ 
translation from an upstream in-phase ATG codon.  This minor form was not 
detected in human and its signiﬁ  cance remains unclear.    Conclusion: We
conclude that the 34kD EMAP-II form is highly conserved in mammals, and 
in addition to its central role in protein translation in all cells, may ‘moonlight’ 
as an immunosuppressive molecule under certain tumour conditions.
Reference:
(1) Quevillon et al., (1997). J. Biol. Chem. 272 (51) : 32573-9
(2) Murray et al. (2004). J Immunol 172:274.
P142
ACTIVATION OF FIBROBLAST GROWTH FACTOR 8 (FGF8) 
EXPRESSION BY TRICHOSTATIN A: A POTENTIAL ROLE FOR 
PI3 KINASE
K Armstrong, V .J. Gnanapragasam, K Halkidou, C.N. Robson, H.Y. Leung 
Northern Institute for Cancer Research, University of Newcastle upon
Tyne, Newcastle upon Tyne, United Kingdom
FGF8 expression is tightly controlled in embryogenesis and carcinogenesis 
[1]. As histone acetyltransferases (HATs) and histone deacetylases (HDACs) 
critically regulate gene expression [2], we tested the role of acetylation in the 
transcriptional control of FGF8 expression by challenging human prostate
cancer cells with trichostatin A (TSA), a reversible HDAC inhibitor.
Transfecting a human  fgf8 promoter-luciferase reporter construct into  8
PC3M prostate cancer cells, we observed a 4-6 fold induction of promoter 
function by TSA (200nM) treatment. Endogenous FGF8 expression in 
LNCaP and PC3M cells was up-regulated in a dose dependent manner 
by TSA treatment, with a maximal effect observed at 200nM. Promoter 
deletion reporter assays revealed a region 996-1613bp upstream of the 
transcriptional start site to be required for TSA induced promoter activity. 
PI3 kinase has been implicated as a mediator of HDAC inhibitor function 
[3]. TSA induced fgf8 promoter reporter function and endogenous FGF8  8
expression were abolished by speciﬁ   c inhibition of PI3 kinase with 
LY294002  (25µM). WST-1 assays showed reduced proliferation with 
increasing TSA concentrations, and FACS analysis conﬁ  rmed cell cycle 
arrests at G1/0 and G2/M in prostate cells (LNCaP, DU145 and PC3M) 
treated with TSA at 20nM and 2µM respectively. However, using a speciﬁ  c 
neutralising antibody against FGF8, we excluded FGF8 as a mediator in 
the suppression of proliferation. Our ongoing work aims to deﬁ  ne the 
functional and in vivo signiﬁ  cance of TSA induced FGF8 expression.
References: [1] Leung, H. Y., C. Dickson, C. N. Robson and D. E. Neal
(1996) Oncogene 12(8) 1833. [2] Timmermann, S., H. Lehrmann, A.
Polesskaya and A. Harel-Bellan (2001) Cell Mol Life Sci 58(5-6) 728. [3]
Kim, Y. K., J. W.Han, Y. N. Woo, J. K. Chun, J. Y. Yoo E. J. Cho, S. Hong,
H. Y. Lee, Y. W. Lee, and H. W. Lee (2003) Oncogene 22(38) 6023.
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ACQUISITION OF ENDOCRINE RESISTANCE: CHANGES 
IN TRANSCRIPTION COMPLEX ASSEMBLY IN RESISTANT 
HUMAN BREAST CANCER CELL LINES.
B Kuske, K MacLeod, C Naughton, K Moore, A O’Donnell,
R Clarke, W Miller, S Langdon, D Cameron
Cancer Research Centre, University of Edinburgh, Edinburgh,
United Kingdom
Endocrine therapy is a major treatment modality for breast cancer. However,
despite initial responsiveness to anti-oestrogens, most tumours will eventually 
recur with acquired anti-oestrogen resistance. Knowledge on the pathways
responsible  for the  development of endocrine resistance remains  limited.
Oestrogen activation  involves oestrogen receptor binding to DNA with 
subsequent cyclic assembly of a transcription complex at speciﬁ  c promoters
incorporating cofactors such as the p160 family (Cell, Vol 103, 843,2000). As
part of a study designed to identify potential resistance mechanisms, we have
investigated oestrogen receptor (ER) mediated transcription activation at the
pS2 promoter in resistant variants of the MCF-7 cell line.
Oestrogen sensitive MCF-7 human breast cancer cell were compared with 
variant LCC1, LCC2, LCC9 and LY2 lines which exhibit relative degrees 
of oestrogen  insensitivity. Using quantitative RT-PCR, we observed t hat 
addition of 1nM E 2 for 48h increased pS2 mRNA by 100-fold in MCF-
7 cells, but only 2-4 fold in all 4 variant cells where expression in the 
absence of E2  was constitutively high. These results broadly reﬂ  ect the 
growth response to E2 in these lines. Expression levels of a number of ER 
coregulators (AIB, SRC-2, SRC-1, REA, NCoR, SMRT) were determined 
by RT-PCR and Western blot. Several coregulators showed differential 
expression.Using chromatin immuno-precipitation we identiﬁ  ed increasing 
H4 acetylation (indicating active transcription), recruitment of ERα and the  α
cyclic recruitment of AIB at the pS2 promoter in MCF-7 cells on addition 
of E2. In contrast, in LCC1 cells, we detected  constant H4 acetylation and 
recruitment of ERα and AIB on E α 2 addition. Interestingly, LCC9 cells show 
active constitutive H4 acetylation but no recruitment of ERα or AIB on E2
addition. These results reveal considerable differences in the assembly of a 
transcription complex in ER mediated gene transcription at the pS2 promoter 
and may help identify oestrogen-independent mechanisms.
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MODIFED SER118 PHOSPHORYLATION OF OESTROGEN 
RECEPTOR  MAY CONTRIBUTE TO ENDOCRINE RESISTANCE 
IN BREAST CANCER CELLS
K Moore, C Naughton, B Kuske, K MacLeod, R Clarke, J Smyth,
W Miller, D Cameron, S Langdon 
Cancer Research Centre, University of Edinburgh, Edinburgh,
United Kingdom
Changes in oestrogen receptor (ER) activation may cause endocrine
insensitivity and resistance in breast cancer (BC) by ligand-independent
stimulation  of ERα phosphorylation of serine residues  in the AF-
1 region of t he receptor. Such p hosphorylations contribute to ER
activation ( by enhancing cofactor binding) and can be mediated via
Erk and Akt which phosphorylate Ser118 and Ser167 respectively. These
processes are stimulated  by growth factors and may be most relevant in
tumours where the EGF receptor or erbB2 are overexpressed.
We are currently  examining these pathways in a series of endocrine-
resistant MCF-7 resistant cell lines (LCC1, LCC2 and LCC9) which are
relatively insensitive to both E2and anti-oestrogens (in contrast to wild type
MCF-7). Changes in ER phosphorylation have been evaluated by Western
blotting using phospho-speciﬁ  c antibodies after exposure to E2 (1nM)
and tamoxifen (TAM; 1µM) in culture. While E2 markedly stimulates
Ser118 p hosphorylation  in the MCF-7 wild type line  (at  least 5-fold),
phosphorylation remains at a constantly low level in LCC9 cells. TAM
also stimulates phosphorylation in the wild type MCF-7 line when added
in the absence of E2 but reduces the level of phosphorylation produced
by E2when both are present together. In the LCC1 and LCC2 lines,  the
E2-activated level of Ser118 phosphorylation is not fully reduced by TAM.
TGFα  (1nM) also stimulates Ser α 118 phosphorylation but with a band
shift pattern different to that produced by E2 or TAM. M. M  These mechanisms
are currently being investigated in primary breast cancers by relating
phosphorylation events to DNA binding and downstream transcription of
E2-regulated genes. These results suggest that in endocrine-resistant cells,
ER-α might be poorly phosphorylated by E2  and/or  TAM may be unable
to reverse fully the E2-activated phosphorylation.
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MFISH IDENTIFIES KARYOTYPIC VARIATION BETWEEN 
INDEPENDENTLY CULTURED STRAINS OF THE MDA-MB231 
BREAST CANCER CELL LINE
MB Watson, MJ Lind, PJ Drew, L Cawkwell 
PGMI, University of Hull, HULL, United Kingdom
Established cell lines derived from breast cancers provide important
models, which can be used to study the genetics, biochemistry and 
dynamics of breast cancer in vitro.  However, the very nature of these
cell lines, along with their widespread and prolonged culture in plastic,
may eventually lead to genotypic and phenotypic variations between
strains cultured by different research groups.  The aim of this study was
to investigate the in vitro genetic divergence at the chromosome level of 
the breast cancer cell line MDA-MB231.  
Multicolour ﬂ  uorescence in situ hybridisation (MFISH) allows rapid 
detection, discrimination and karyotyping of all chromosomes within a
single metaphase spread.  Strains of MDA-MB231 were obtained from
3 different laboratories (Hull, York & USA) and subjected to MFISH
analysis. 
As expected, many Karyotypic aberrations were identiﬁ  ed,  which
were common to all strains of this cell line.  For example, the marker 
chromosomes derivative(2)t(2;12;8) and der(2)t(8;2).  However,
several other unique abnormalities were identiﬁ   ed between strains
enabling the production of a map of Karyotypic divergence.  For 
example der(6)t(6;19;12;8), which was unique to the hull strain and 
der(19)t(19;X;5), which was unique the USA strain.  This study
identiﬁ  es the need for the potential genetic divergence of cell lines
cultured extensively in the laboratory to be taken into account during
the interpretation of experimental data.
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HYPOXIA-REGULATED GENE EXPRESSION IN 
RHABDOMYOSARCOMA CELL LINES
N Hermitage 1, A Evans 1, P Houghton 2, I Stratford 3, E Estlin 4,
R Airley 1
1 Liverpool John Moores University, Liverpool, United Kingdom,
2 St Judes Childrens Research hospital, Memphis, United States,
3 University of Manchester, Manchester, United Kingdom, 4 Royal 
Manchester Childrens Hospital, Manchester, United Kingdom
Rhabdomyosarcoma, the most common type of paediatric soft tissue
sarcoma, is denoted by high malignancy, a thirty percent mortality rate,
with peak incidence in 1-4 year olds. Hypoxia is frequently observed in
solid tumours within areas of rapid cell proliferation served by quantitatively
and/or qualitatively poor vascularity. To increase intracellular nutrients
during  hypoxic stress, malignant cells adapt through up-regulation of
hypoxia-inducible genes such as the facilitative glucose transporter-1 Glut-
1.  Tumours with a high hypoxic fraction have less favourable prognosis and
poor treatment response. This has been demonstrated for cancers of the head
and neck, and cervix. Glut-1 is over expressed and predicts poor prognosis
in a wide range of tumours, and has been clinically validated as an intrinsic
marker of hypoxia.  In paediatric oncology intense drug and radiation
therapy has to be balanced against the risks of late sequelae such as growth
and development retardation.  Rational application of aggressive treatment to
hypoxic areas of the tumour may be one way of overcoming this therapeutic
problem.  We have recently found that Glut-1 and Glut-3 are expressed peri-
necrotically in 10/20 and 7/14 rhabdomyosarcoma samples respectively. y. y  To
complement these ﬁ  ndings, we have assessed the expression of hypoxia-
medicated  genes Glut-1, Glut-3 and VEGF in rhabdomyosarcoma cell
lines.  Immunohistochemistry was carried out on formalin-ﬁ  xed, parafﬁ  n-
embedded pellets of Rh30 and Rh36 cell lines following 18 hours in anoxic
conditions.   In both cell lines, there was no constitutive Glut-1 expression
but after exposure to anoxia moderate to heavy Glut-1 expression was
apparent. Glut-3 was detected in RH36 cells at equal levels in normoxic and
anoxic samples, but there was no Glut-3 detected in RH30 cells. Therefore,
the Glut-1 seen in biopsy samples may reﬂ  ect the existence of hypoxia in the
tumour, but other factors may be regulating tumour Glut-3.
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AN INDUCIBLE SYSTEM OF GENE EXPRESSION PROVIDES 
THE MEANS TO INVESTIGATE THE FUNCTIONS OF OPCML
E. Ntougkos 1, G.J. Rabiasz 1, E.P. Miller 1, H. Gabra 2,
J.F. Smyth 1, G.C. Sellar 1
1 Cancer Research UK, Edinburgh, United Kingdom, 2 Imperial 
College, London, United Kingdom
OPCML, alternatively known as OBCAM ( M Opioid  Opioid  O Binding Cell  Cell  C Adhesion 
Molecule), encodes a member of the IgLON subfamily of cell adhesion  Molecule), encodes a member of the IgLON subfamily of cell adhesion  M
molecules. OPCML is frequently inactivated in epithelial ovarian cancer 
(EOC) and exhibits properties of a tumour suppressor gene, such as
growth suppression in vivoand in vitroand enhanced cell-cell aggregation 
in vitro. It is the ﬁ  rst IgLON reported to be involved in cancer.
We have employed an inducible system of gene expression to investigate
the basic biology of OPCML. The BD Tet-OnTM system allows tightly 
regulated expression after induction with doxycycline, while avoiding
obstacles of clonal variation and over-expression artefacts. Two OPCML
inserts have been expressed in HeLa Tet-OnTM cells: a wild-type OPCML
coding sequence and one harbouring a loss-of-function mutation that 
occurs in EOC. The wild-type and mutant clones exhibit dose-dependent 
OPCML expression. Tight regulation of OPCML expression, with 
minimal leaky expression, is evident both at the RNA level, according
to real-time RT-PCR data, and at the protein level, according to western 
blotting. RNA and protein data are well correlated.
We are currently using this platform of investigation, and assays that
examine cellular properties, such as cell growth and attachment, in
order to unravel the functions of OPCML. In addition to the pursuit of 
a cellular phenotype in the context of HeLa cells, we are also interested 
in the importance of the level of OPCML expression in effecting this
phenotype. Preliminary evidence suggests that although induction of 
OPCML does not result in overt growth suppression, it may account
for an increased attachment to extracellular matrix components, such as
ﬁ  bronectin.  The signiﬁ  cance of a cell attachment-related phenotype in
HeLa cells will be validated further.
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EXPRESSION OF CHEMOKINES IL-8 AND GCP-2 AND THEIR 
RECEPTORS CXCR1 AND CXCR2 IN SMALL AND
NON-SMALL CELL LUNG CANCER CELL LINES
YM Zhu, D Flower, PJ Woll 
University of Shefﬁ  eld, Shefﬁ  eld, United Kingdom
Interleukin (IL)-8 and Granulocyte chemotactic protein (GCP)-2 are
potent chemokines and angiogenic  factors that  both act through t he
CXCR1 and CXCR2 receptors. Here, we studied the expression of IL-8,
GCP-2, CXCR1 and CXCR2 in 3 non-small cell lung cancer (NSCLC)
cell lines and 5 small cell lung cancer (SCLC) cell lines. 
Results:  IL-8 and GCP-2 proteins were measured by ELISA in conditioned
medium (CM). NSCLC cells produced high levels of IL-8 at 24 hours (196,
6153 & 584 pg/ml/106  of A549, H460 & MOR/P, respectively) and at 48
hours (1227, 134615 & 7299 pg/ml) whereas IL-8 was very low or absent in
CM of SCLC.  In contrast, SCLC cells produced high levels of GCP-2 at 24
hours (390, 1935, 38 & 125 pg/ml/106   of H345, H711, GLC-19 & Lu165,
respectively) and at 48 hours  (781, 3225, 128 & 125 pg/ml), whereas
NSCLC did not produce GCP-2. We studied the expression of CXCR1
and CXCR2 by FACS in these cell lines. In NSCLC cell lines, 32-47%
of cells expressed CXCR1 and 9-28% expressed CXCR2.  In SCLC cell
lines, 28-56% of cells expressed CXCR1 and 8-38% expressed CXCR2.
Expression of CXCR1 and CXCR2 mRNA was also assessed by RT-PCR
and the results were in agreement with FACS analysis.  To investigate the
potential mitogenic role of IL-8 in lung cancer, we treated IL-8 producing
NSCLC cells with neutralising anti-IL-8 antibody and non-IL-8 producing
SCLC cells with exogenous IL-8. Cell proliferation was determined by
MTT assay. NSCLC cell proliferation was signiﬁ  cantly inhibited by anti-
IL-8 antibody in a dose-dependent fashion. The SCLC cells were stimulated
by rIL-8 in a dose- and time-dependent fashion.
Conclusion:  Our results show that SCLC and NSCLC cells express
CXCR1 and CXCR2 receptors. We have  found signiﬁ  cant differences
in ligand expression, as NSCLC cells produce IL-8 whereas SCLC
cells produce GCP-2.  IL-8 is mitogenic for lung cancer cells.  CXC
chemokines may therefore be a novel target for lung cancer treatment.
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THE INDUCTION AND MAINTENANCE OF SENESCENCE IN
HCT116 CELLS BY DNA DAMAGING AGENTS
A.O Oke, S.P Joel 
Department of Medical Oncology, St Bartholomew’s Hospital,
West Smithﬁ  eld, London, United Kingdom
Senescence is a major tumour suppressor mechanism limiting the
proliferative capacity of cells in vivo, and is a major barrier to
tumorigenesis. We have previously showed that the topoisomeraese-I
inhibitor SN-38 (the active metabolite of irinotecan) is able to induce
senescence in tumour cells expressing wild-type p53, and that p21 plays
a central role in the onset of senescence, which is then maintained by
p16 (te Poele et al, Can Res 62, 1876–1883, 2002). We have investigated 
this further using the HCT116 colorectal cell line panel (including p53wt,
p53-/- and p21-/- cells), which have a hypermethylated p16 promoter.
SN-38 induced G2 arrest was seen in all cells, but subsequent cell death
was more extensive in p53-/- and p21-/- cells than in p53wt cells that
remained viable but arrested and stained +ve for β-galactosidase (β-gal)
activity. At high drug concentration (100 ng/ml) surviving p53-/- and 
p21-/- cells, although low in number, also stained +ve for β-gal, but lost
this activity and resumed growth after 8 days in drug-free medium.   In
contrast, p53wt cells did not lose β-gal staining nor resumed growth until
22 days drug-free, conﬁ  rming the importance of p16 in maintaining
senescence. Additionally, p53wt cells in which senescence had been
induced by exposure to SN-38 showed decreased sensitivity to taxol,
5-FU and cisplatin compared to control cells using the sulphorhodamine
blue assay.
These data conﬁ  rm the importance of p53 and p21 in the induction of 
senescence. Failure to maintain senescence in HCT116 p53wt cells is
likely to be due to silencing of the p16 gene by hypermethylation. The
decreased sensitivity of senescent cells to subsequent cytotoxic drug
exposure may have clinical signiﬁ  cance. We are currently investigating
pathways involved in the induction and loss of the senescent phenotype
in these cells using expression microarrays.
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REGULATION OF CXCR1 AND CXCR2 RECEPTORS IN
NSCLC CELL LINES
S Webster, YM Zhu, PJ Woll 
University of Shefﬁ  eld, Shefﬁ  eld, United Kingdom
Interleukin-8  (IL-8) is a chemokine with angiogenic and mitogenic
effects in cancer.  Expression of IL-8 in non-small cell lung cancer
(NSCLC) is associated with angiogenesis, metastasis, and poor patient
outcome.  We have identiﬁ  ed IL-8 as a putative autocrine growth factor
for NSCLC. Here, we investigated the cell surface expression of CXCR1
and CXCR2 by ﬂ  ow cytometry in 3 NSCLC cell lines, and regulation of
receptor expression by cell density and endogenous IL-8.
Results:  Cell membrane expression of CXCR1 and CXCR2 was
detected by ﬂ  ow cytometry. CXCR1 were more commonly expressed
than CXCR2.  Interestingly, higher numbers of both receptors were
detected when cells were removed from the ﬂ  asks by scraping than by
trypsinisation: 45% vs 12% for CXCR1 in H460 cells, 40% vs 14% in
MOR/P cells and 32% vs 4% in A549 cells.  For CXCR2, 20% vs 9%
in H460 cells, 9% vs 5% in MOR/P and 13% vs 3% in A549 cells. We
further analysed cell membrane CXCR1 and CXCR2 in 50% and 100%
conﬂ  uent cells. We found that totally conﬂ  uent cells expressed much
lower levels of CXCR1 and CXCR2 than 50% conﬂ  uent. The CXCR1
positive cells were downregulated from 43% to 22% in H460 and 25%
to 15% in MOR/P. The CXCR2 positive cells were downregulated from
28% to 6% in H460 and 9% to 6% in MOR/P.  H460 and MOR/P cells
constitutively produced IL-8. IL-8 concentration measured by ELISA
was 65ng/ml  in H460 and 3.5 ng/ml  in MOR/P when cells were
conﬂ  uent at 48h. IL-8 concentration was halved in H460 and in MOR/P
when cells were 50% conﬂ  uent. These results suggest that CXCR1 and
CXCR2 might be internalised at higher concentrations of IL-8.
Conclusions:  Our results suggest that CXCR1 and CXCR2 are
commonly expressed on NSCLC cell membranes and their expression
is affected by cell density.  Downregulation of membrane CXCR1 and
CXCR2 (internalization) in high density cells may be affected by higher
level of endogenous IL-8 in the medium.
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